Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an announcement.
Telix Pharmaceuticals has priced and upsized a new five-year US$600 million issue of 1.50% convertible bonds, following strong global investor demand, with the notes convertible into ordinary shares at a 37.5% premium to the A$14.22 reference price. The bonds, issued via a U.S. subsidiary and listed on SGX, enhance Telix’s access to long-dated, low-cost capital.
Proceeds will largely be used to refinance Telix’s existing A$650 million convertible bonds due 2029, with about A$637 million to be repurchased and more than 85% of that issue cancelled under a concurrent reverse bookbuild. The transaction, supported by a delta placement of shares managed by J.P. Morgan, strengthens the company’s capital structure and financial flexibility while limiting near-term refinancing risk for investors.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.60 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, it operates across the U.S., U.K., Europe, Brazil, Canada and Japan, and its shares trade on both the ASX and Nasdaq.
Average Trading Volume: 3,255,785
Technical Sentiment Signal: Buy
Current Market Cap: A$4.96B
Learn more about TLX stock on TipRanks’ Stock Analysis page.